Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion recommending an expansion of Pepaxti's (melflufen) label, in combination with dexamethasone, from fourth-line to third-line multiple myeloma. The opinion now goes to the European Commission for a final decision.
LÄS MER
